Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Page Banner for mobile screens

ASCO 2024 Preview: Top Bi-specific Antibodies expected Data readouts

Bi-specific Antibodies ASCO 2024 Preview

Bispecific antibodies, a novel class of immunotherapies, are showing significant promise in oncology. These engineered antibodies can simultaneously bind to two different antigens, providing unique mechanisms of action. Hematological malignancies are the primary focus of bispecific antibody development. Fast forward to 2022–2023, and we witnessed a dynamic shift, with eight new bispecific approvals, primarily revolutionizing hematological cancer treatments.  Nevertheless, numerous bispecific antibodies are under investigation for various solid tumors, including gastric, colorectal, ovarian, prostate, and Lung cancer.

Johnson & Johnson, Betta Pharmaceutical, Curon Biopharmaceutical, AkesoBio, Genmab, Innovent Biologics, and others are poised to showcase their latest research and advancements in bispecific treatments at the ASCO 2024. One of the major highlight of the conference will be the presentation of data on innovative molecules like the first-in-class PD-1/IL-2 bispecific antibody, IBI363, for patients with advanced colorectal cancer.

DelveInsight has put together leading bi-specific abstracts, eagerly anticipating their top data readouts.

Bispecific Key Abstracts

Company

Drug

Trial ID/ Acronym

Phase

Abstract ID

Abstract Title

Amivantamab

NCT05388669/

PALOMA-3

III

Oral Abstract Session - LBA8505

Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, Phase III, randomized controlled PALOMA-3 trial

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

MCLA-129

NCT04930432

I/II

Poster Session - 8604, Abstract- 468

Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)

Teclistamab

NCT05552222/

MajesTEC-7

III

Oral Abstract Session - 7506 

Safety results from the Phase III MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM)

CN201

NCT06189391

I

Poster Session -

23, Abstract- 7040

Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Epcoritamab

NCT04663347/

EPCORE NHL-2

Ib/II

Poster Session -

65, Abstract- 7082

Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2

IBI363

NCT05460767

Ia/Ib

Poster Session - 256, Abstract- 3593

First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a Phase I study.

Cadonilimab + pulocimab + paclitaxel

NCT04982276

I/II

Rapid Oral Abstract Session - 4012

Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial.

 

Tags:

Executive Summary

Johnson & Johnson, Betta Pharmaceutical, Curon Biopharmaceutical, AkesoBio, Genmab, Innovent Biologics, and others are poised to showcase their latest research and advancements in bispecific treatments at the ASCO 2024.

Recent Articles